Sandoz to Invest Over $400 Million in New Biologics Plant in Slovenia

Sandoz to Invest Over $400 Million in New Biologics Plant in Slovenia

(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has signed a Memorandum of Understanding to build a new biologics production plant in Lendava, Slovenia, in a move expected to be worth at least USD 400 million. The plant is set to become a major new part of Sandoz’s operations and will meet growing demand for current and future biosimilars. The project is expected to start work this year, with full operations set to begin in late 2026. The announcement comes after the company recently committed to an additional EUR 50 million investment to expand its European-based antibiotics production network.

(PRESS RELEASE) BASEL, 10-Mar-2023 — /EuropaWire/ —Sandoz, a global leader in generic and biosimilar medicines, signed a Memorandum of Understanding (MOU) to build a new biologics production plant in Lendava, Slovenia.

The Sandoz investment is expected to be at least USD 400 million, supporting the company’s ambition to drive the future growth of its global biosimilars portfolio. This represents one of the largest-ever international private-sector investments in Slovenia.

Speaking at the signing ceremony, Dr Robert Golob, Prime Minister of the Republic of Slovenia, said: “I am particularly pleased that this is an investment by a long-term strategic investor, a socially responsible and sustainable company, which is already one of the largest and most respected employers in Slovenia. With such investments, we are well on our way to a highly productive, competitive and green economy.”

Sandoz CEO Richard Saynor said: “Biosimilar medicines increase access to cutting-edge biologic therapies for the patients who need them most. At Sandoz, we are determined to continue leading the way on driving access to these critical medicines. This investment underscores our ambition to be the sustainable global leader in biosimilars, a segment projected to grow double-digit annually over the next decade.”

Glenn Gerecke, Global Head of Sandoz Technical Operations, added: “This state-of-the-art site will be a major new jewel in the Sandoz crown, enabling us to meet growing demand for our current and future biosimilars in the mid- to long-term. The location offers us a strong combination of political stability, proximity to our existing European-based production and commercial operations, and competitive costs.”

Work on the new plant is set to begin this year, with full operations provisonally planned for late 2026.

Sandoz also recently announced an additional EUR 50 million investment to expand its European-based antibiotics production network, bringing the total new investment commitment to the network in the past few years to EUR 250 million. Anti-infectives (primarily antibiotics) is the second largest Sandoz business after Biopharmaceuticals, and both have their roots in the company’s unique 75-year history of developing fermentation-based production technologies.

Sandoz is a pioneer and market leader in biosimilars and the leading global producer of generic antibiotics. The company is committed to building on its leadership role in these two critical and growing segments of the off-patent medicines market.

Disclaimer 

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2022 sales of USD 9.2 billion.

Sandoz on social media:

LinkedIn: https://www.linkedin.com/company/sandoz
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

Media Contact:

Michelle Bauman
Global Head External Affairs
Mobile +1 973-714-8043

Chris Lewis
Director, Financial Communications
Phone: +49 8024 476 1906

SOURCE: Sandoz

MORE ON SANDOZ, ETC.:

Follow EuropaWire on Google News
EDITOR'S PICK:

Comments are closed.